Pacira BioSciences, Inc.PCRXEarnings & Financial Report
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
Revenue
$168.6M
Gross Profit
$129.7M
Operating Profit
$-139.5M
Net Profit
$-143.5M
Gross Margin
76.9%
Operating Margin
-82.8%
Net Margin
-85.1%
YoY Growth
2.8%
EPS
$-3.11
Pacira BioSciences, Inc. Q3 FY2024 Financial Summary
Pacira BioSciences, Inc. reported revenue of $168.6M (up 2.8% YoY) for Q3 FY2024, with a net profit of $-143.5M (down 1421.3% YoY) (-85.1% margin). Cost of goods sold was $38.9M, operating expenses totaled $269.2M.
Key Financial Metrics
| Total Revenue | $168.6M |
|---|---|
| Net Profit | $-143.5M |
| Gross Margin | 76.9% |
| Operating Margin | -82.8% |
| Report Period | Q3 FY2024 |
Pacira BioSciences, Inc. Annual Revenue by Year
Pacira BioSciences, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $726.4M).
| Year | Annual Revenue |
|---|---|
| 2025 | $726.4M |
| 2024 | $701.0M |
| 2023 | $675.0M |
| 2022 | $666.8M |
Pacira BioSciences, Inc. Quarterly Revenue & Net Profit History
Pacira BioSciences, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q1 FY2026 | $177.4M | +5.0% | $2.9M | 1.6% |
| Q4 FY2025 | $196.9M | +5.1% | N/A | N/A |
| Q3 FY2025 | $179.5M | +6.5% | $5.4M | 3.0% |
| Q2 FY2025 | $181.1M | +1.7% | $-4.8M | -2.7% |
| Q1 FY2025 | $168.9M | +1.1% | $4.8M | 2.8% |
| Q4 FY2024 | $187.3M | +3.3% | N/A | N/A |
| Q3 FY2024 | $168.6M | +2.8% | $-143.5M | -85.1% |
| Q2 FY2024 | $178.0M | +5.0% | $18.9M | 10.6% |
Income Statement
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $178.0M | $168.6M | $187.3M | $168.9M | $181.1M | $179.5M | $196.9M | $177.4M |
| YoY Growth | 5.0% | 2.8% | 3.3% | 1.1% | 1.7% | 6.5% | 5.1% | 5.0% |
Balance Sheet
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $1.65B | $1.52B | $1.55B | $1.59B | $1.54B | $1.30B | $1.26B | $1.21B |
| Liabilities | $767.5M | $772.1M | $775.2M | $788.1M | $779.5M | $570.4M | $571.8M | $554.6M |
| Equity | $879.3M | $749.6M | $778.3M | $798.5M | $757.8M | $727.2M | $693.1M | $653.9M |
Cash Flow
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|
| Operating CF | $53.2M | $53.9M | $33.1M | $35.5M | $12.0M | $60.8M | $43.7M |